Browsing Tag
National Institute of Allergy and Infectious Diseases
1 post
Appili Therapeutics faces funding reset after NIAID terminates VXV-01 contract
Appili Therapeutics faces a funding reset after NIAID ended its VXV-01 contract. Discover what the termination means for APLI investors.